Patient-derived xenografts and organoid models revealed that roblitinib, a selective FGFR4 inhibitor (also known as FGF-401), is effective in both intrinsic and acquired anti-HER2-resistant breast cancers (106). Here, FGFR4 is linked to breast cancer.